Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cancer Therapy AdvisorClinical and Molecular Features of HER2-Low Breast Cancer

Guideline-directed binary distinctions between HER2-positive and HER2-negative breast cancer have guided physicians’ treatment decisions for quite some time, but new research suggests that patients with HER2-2+, ISH-negative breast cancer present a clinical picture closer to that of patients with HER2-positive breast cancer, offering up a new nomenclature, HER2-low.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form